The new migraine injection
If you suffer from migraine and you feel as if it’s impacting your relationships, work and personal life, you’re not alone. Migraine is the third most common disease worldwide, affecting around 1 in 7 people*. If you feel like you’ve used all treatment options and nothing has worked, you’re not alone either. Many migraine patients feel like painkillers and other migraine medicines do not work for them, or they can’t take them long-term. But now there’s a new hope.*According to The Migraine Trust
Please note this page contains information about overseas approved prescription medicines. This includes transparent information such as clinical trials published, how the product works and pricing. If you scroll down, you declare yourself as requesting this information.
The newly approved migraine injection
Erenumab (Aimovig) is the first approved migraine injection that could offer new hope for people who suffer from migraine. According to the Food and Drug Administration (FDA), erenumab (Aimovig) is, globally, the first and only approved CGRP receptor blocker and the first in a new class of preventative migraine medicines1.
What is erenumab (Aimovig)?
Erenumab (Aimovig) is an injection for migraine, which is taken once per month. Clinical studies published by the FDA show that it may offer relief for people with chronic and episodic migraine, by blocking specific molecules that are thought to play a role in migraine.2 Aimovig was also approved by the Therapeutic Goods Administration (TGA) in 2018, and shortly after by the Swissmedic, European EMA and Health Canada3,4,5,6.
Read here for more information about treatment expenses and availability.
How effective is erenumab (Aimovig) according to the studies?
- Aimovig 70 mg
- Aimovig 140 mg
How to use the new migraine injection (erenumab)*
How do these new blockers like erenumab (Aimovig) work?
How can I get erenumab (Aimovig)?
It may be the case that erenumab is not yet approved or available in your country, which may mean you will experience delays in accessing this medicine. We’re here to help.
With a prescription from your treating doctor TheSocialMedwork can support you to obtain erenumab (Aimovig) from outside your country. Our team of pharmacists and regulatory experts delivers elsewhere approved medicines around the world every day. They are ready to assist with sourcing and delivery, and will guide you through every step of the process.Enquire Now
Migraine is a challenging and under-recognised disorder. If you’d like to ask questions about erenumab (Aimovig), how to get it, or about any other migraine treatments, our team of qualified pharmacists and experts are ready to offer support and assist with queries. Our team speaks 17 different languages and is ready to help.
Who is TheSocialMedwork?
TheSocialMedwork makes the latest approved medicines available to patients, hospitals and doctors around the world, in a legal and compliant way. We source the best possible prices for innovative medicines and ensure safe, efficient and legally compliant delivery. We have successful deliveries in over 60 countries worldwide, with 100% quality service reviews by doctors and patients.
- FDA approves novel preventive treatment for migraine. 17/05/2018. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm608120.htm
- Aimovig. Cited 18/07/2018. www.aimovig.com
- TGA Public Summary: Aimovig [PDF], July 2,2018.
- Novartis-Migränemedikament Aimovig wird in der Schweiz zugelassen, Luzerner Zeitung, July 16, 2018.
- Novartis Press Release: Novartis marks a new era for migraine patients with the EU approval of Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention,
July 30, 2018.
- Novartis Press Release: AimovigTM (erenumab), a novel treatment developed specifically for migraine prevention receives Health Canada approval,
August 1, 2018.
- CGRP as the target of new migraine therapies. Edvinsson L. et al. Nature Reviews Neurology. 24/04/2018; volume 14: 338–350.